| Parameter | Scenario | |||
|---|---|---|---|---|
| 1. Asymptomatic people not at high risk for HCV infection | 2. Immigrant populations with high prevalence | 3. Specific birth cohort (25-64 yr) | 4. Specific birth cohort (45-64 yr) | |
| Cost of dasabuvir plus ombitasvir-paritaprevir-ritonavir, $9 | 55 860 | 55 860 | 55 860 | 55 860 |
| Cost of ledipasvir plus sofosbuvir, $9 | 67 000 | 67 000 | 67 000 | 67 000 |
| Cost of pegylated interferon-ribavirin, $9 | 19 075 | 19 075 | 19 075 | 19 075 |
| Prevalence of HCV infection (range) | 0.2 (0.10-0.30)3 | 1.9 (1.30-2.60)3 | 14-49 yr: 0.4 (0.2-0.7) 50-79 yr: 0.8 (0.4-1.5)2 | 14-49 yr: 0.4 (0.2-0.7) 50-79 yr: 0.8 (0.4-1.5)2 |
| Uptake of screening (range), %* | 89.5 (70-100) | 76.6 (60-100) | 89.5 (60-100) | 90 (76-100) |
| Uptake of treatment (range), %* | 80 (80-100) | 95 (80-100) | 95 (80-100) | 80 (80-100) |
| Known chronic HCV infection2 | 0.305 | 0.305 | 0.305 | 0.305 |
| Age distribution10 | 15-24 yr: 0.17 | 15-24 yr: 0.10 | 25-34 yr: 0.20 | 45-54 yr: 0.54 |
| 25-34 yr: 0.17 | 25-34 yr: 0.15 | 35-44 yr: 0.27 | 55-64 yr: 0.46 | |
| 35-44 yr: 0.17 | 35-44 yr: 0.21 | 45-54 yr: 0.29 | - | |
| 45-54 yr: 0.20 | 45-54 yr: 0.22 | 55-64 yr: 0.24 | - | |
| 55-64 yr: 0.16 | 55-64 yr: 0.19 | - | - | |
| 65-74 yr: 0.10 | 65-74 yr: 0.10 | - | - | |
| 75-79 yr: 0.03 | 75-79 yr: 0.03 | - | - | |
| Distribution of fibrosis stage for all cohorts (range), %* | Age 15-34 yr | Age 35-44 yr | Age 45-54 yr | Age 55-79 yr |
| F0 | 45 (30-35) | 10 (5-15) | 5 (0-10) | 5 (0-10) |
| F1 | 45 (30-55) | 43 (30-60) | 25 (15-30) | 10 (5-15) |
| F2 | 8 (5-20) | 13 (13-60) | 25 (25-45) | 15 (10-20) |
| F3 | 1 (0-5) | 19 (5-20) | 25 (20-30) | 45 (40-60) |
| F4 | 1 (0-5) | 15 (0-20) | 20 (5-35) | 25 (15-40) |
Note: HCV = hepatitis C virus.
*Clinical experts' opinion.